Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: In clear cell renal cell carcinoma, 80% of cases have biallelic inactivation of the VHL gene, leading to constitutive activation of both HIF1α and HIF2α. As HIF2α is the driver of the disease promoting tumour growth and metastasis, drugs targeting HIF2α have been developed. However, resistance is common, therefore new therapies are needed. METHODS: We assessed the effect of the HIF2α antagonist PT2385 in several steps of tumour development and performed RNAseq to identify genes differentially expressed upon treatment. A drug screening was used to identify drugs with antiproliferative effects on VHL-mutated HIF2α-expressing cells and could increase effectiveness of PT2385. RESULTS: PT2385 did not reduce cell proliferation or clonogenicity but, in contrast to the genetic silencing of HIF2α, it reduced in vitro cell invasion. Many HIF-inducible genes were down-regulated upon PT2385 treatment, whereas some genes involved in cell migration or extracellular matrix were up-regulated. HIF2α was associated with resistance to statins, addition to PT2385 did not increase the sensitivity. CONCLUSIONS: this study shows key differences between inhibiting a target versus knockdown, which are potentially targetable.

Original publication

DOI

10.1186/s12885-021-08616-8

Type

Journal article

Journal

BMC Cancer

Publication Date

05/08/2021

Volume

21

Keywords

Drug resistance, EMT, HIF2α, Renal cancer, Antineoplastic Agents, Basic Helix-Loop-Helix Transcription Factors, Cell Line, Tumor, Cell Movement, Cell Proliferation, Drug Repositioning, Drug Resistance, Neoplasm, Epithelial-Mesenchymal Transition, Gene Expression Profiling, Gene Silencing, Humans, Indans, Kidney Neoplasms, Sulfones, Transcriptional Activation, Transcriptome, Treatment Outcome